Ergomed PLC
LSE:ERGO

Watchlist Manager
Ergomed PLC Logo
Ergomed PLC
LSE:ERGO
Watchlist
Price: 1 346 GBX Market Closed
Market Cap: 701.1m GBX
Have any thoughts about
Ergomed PLC?
Write Note

Ergomed PLC
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ergomed PLC
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Ergomed PLC
LSE:ERGO
Common Shares Outstanding
ÂŁ50.8m
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Common Shares Outstanding
ÂŁ859.2m
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Common Shares Outstanding
ÂŁ84.5m
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Common Shares Outstanding
ÂŁ153m
CAGR 3-Years
34%
CAGR 5-Years
35%
CAGR 10-Years
32%
C4X Discovery Holdings PLC
LSE:C4XD
Common Shares Outstanding
ÂŁ252.2m
CAGR 3-Years
4%
CAGR 5-Years
34%
CAGR 10-Years
N/A
hVIVO PLC
LSE:HVO
Common Shares Outstanding
ÂŁ680.4m
CAGR 3-Years
0%
CAGR 5-Years
22%
CAGR 10-Years
38%
No Stocks Found

Ergomed PLC
Glance View

Market Cap
683.5m GBX
Industry
Life Sciences Tools & Services

Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm operates approximately 24 offices around the world, providing its services in over 100 countries globally. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Company’s subsidiaries include Ergomed GmbH, Ergomed Sp. z o.o, Ergomed d.o.o. Beograd, Ergomed Clinical Research Inc., MS Clinical Services, LLC and MedSource UK Ltd.

ERGO Intrinsic Value
1 143.97 GBX
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Ergomed PLC's Common Shares Outstanding?
Common Shares Outstanding
50.8m GBP

Based on the financial report for Jun 30, 2023, Ergomed PLC's Common Shares Outstanding amounts to 50.8m GBP.

What is Ergomed PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
3%

Over the last year, the Common Shares Outstanding growth was 2%. The average annual Common Shares Outstanding growth rates for Ergomed PLC have been 2% over the past three years , 3% over the past five years .

Back to Top